What Are Lyophilized Peptides? How Lyophilization Works

Lyophilized peptides are peptides that have been freeze-dried into a solid, a manufacturing step used because many peptides are less stable in water.

Basics10 min read

Key takeaway

Lyophilization removes water from a frozen solution in three stages: freezing, primary drying and secondary drying. FDA's inspection guide says products are made in this form because of their instability in solution. Laboratory studies show that dry peptides still degrade, at rates that depend on residual moisture, temperature and the other ingredients in the vial.

At a glance

Article typeBasics
TopicTesting & quality
Studies cited10
Related productsResearch peptide catalog

What are lyophilized peptides? They are peptides that have been frozen and then dried under vacuum, leaving a dry cake or powder in a sealed vial. This page covers how lyophilization works, why it slows degradation, and what laboratory studies and FDA labels show.

Quick answer: A lyophilized peptide is the same peptide molecule in a freeze-dried solid form. Freeze-drying is meant to change the physical state, not the amino acid sequence. Approved peptide medicines supplied this way each list their own storage conditions, from a freezer to room temperature. Research-grade lyophilized peptides have no FDA-reviewed label or expiration date.

What are lyophilized peptides?

A peptide is a short chain of amino acids joined by peptide bonds; the what are peptides guide covers the basics. "Lyophilized" describes a physical form, not a type of molecule. A lyophilized peptide has been dissolved, frozen and dried until most of the water is gone.

FDA's Guide to Inspections of Lyophilization of Parenterals defines it as removing water from a frozen product under vacuum. The ice changes "directly from solid to vapor without passing through a liquid phase," a step called sublimation. The dried solid left in the vial is called the cake.

The cake often holds more than the peptide. The bivalirudin, cetrorelix and human secretin labels each list mannitol as an inactive ingredient. Their peptides are present as acetate or trifluoroacetate salts. Some water also remains, which is why moisture is a tested quality attribute.

Where did lyophilization come from?

The term has roots in 1930s laboratory work on serum. In 1935, Earl Flosdorf and Stuart Mudd of the University of Pennsylvania described a procedure and apparatus for preserving serum and other biological substances. Their title called the dried product the "lyophile" form, the root of the word lyophilization.

The technique later spread to many sterile products. FDA's 1993 guide names some semi-synthetic penicillins, cephalosporins and salts of erythromycin, doxycycline and chloramphenicol as lyophilized products. It adds that many new products, "including anti-infectives, biotechnology derived products, and in-vitro diagnostics," are made this way.

Synthetic peptides also carry traces of how they were made. Cornish and colleagues noted that peptides purified by HPLC "are often in the form of a trifluoroacetate (TFA) salt" because of the solvent used. The peptide synthesis guide covers the steps that come before drying.

How does lyophilization work?

FDA's guide describes three "interdependent processes": freezing, primary drying by sublimation and secondary drying by desorption. Before freezing, the drug and its excipients are dissolved and the solution is sterilized by filtration. Vials are filled and partly stoppered under aseptic conditions, then fully stoppered inside the freeze dryer.

Table 1

How does lyophilization work

StageWhat happensWhat the sources say matters
FreezingThe filled vials are cooled on shelves until the solution freezesFDA: slow freezing forms larger ice crystals that help vapor escape, but it can increase concentration shifts of components
Primary drying (sublimation)A vacuum is applied and the shelves are heated, so ice turns directly into vaporFDA: holding product temperature at least 4 to 5 degrees below the eutectic point is desirable; Tang and Pikal: a target product temperature is set from the collapse temperature and Tg'
Secondary drying (desorption)Remaining water is removed from the solid by desorptionFDA: the moisture limit and expiration date should rest on worst-case moisture data
Sealing and inspectionVials are stoppered in the chamber, then inspectedFDA, citing USP: 100% inspection includes cake appearance, and meltback is a major concern

The freezing step shapes the rest of the process. Tang and Pikal wrote that commercial processes "are often neither robust nor efficient," because design is often trial and error. Their review covers ice nucleation, collapse temperature, the glass transition of the frozen solution (Tg') and the choice of shelf temperature and chamber pressure.

Meltback is the main visible failure. FDA calls it "a form of cake collapse" caused by incomplete sublimation. It can leave a changed physical form or "a pocket of moisture," which FDA says may increase degradation.

Freeze-drying is not a sterilization step. FDA notes that vial contents "are subject to contamination until they are actually sealed," so the guide covers media fills, environmental monitoring and sterility testing. Endotoxin is a separate test, covered in the endotoxin testing guide.

Why are peptides freeze-dried?

The main reason is shelf life. FDA's guide says products are made in lyophilized form "due to their instability when in solution." It lists "enhanced stability of a dry powder" as an advantage. Disadvantages it names include longer processing time and costly, complex equipment.

Wang's 2000 review of solid protein pharmaceuticals makes the same point. Proteins "often have to be made into solid forms to achieve an acceptable shelf life," and lyophilization is the most common way to do it. Wang also warns that the process "generates both freezing and drying stresses," which can denature proteins to various degrees.

Drying slows degradation but does not stop it. Lai and Topp list the main solid-state reactions of peptides and proteins: deamidation, peptide bond cleavage, oxidation, the Maillard reaction, beta-elimination, and dimerization or aggregation. Controlling factors include temperature, moisture content, excipients and whether the solid is amorphous or crystalline.

What does laboratory research show about dry peptide stability?

The studies below are laboratory studies of materials. None involved people or animals, and each tested a specific molecule and formulation.

Table 2

What does laboratory research show about dry peptide stability

StudyMaterial testedWhat was variedMain reported finding
Oliyai et al., 1994Lyophilized model hexapeptide, Val-Tyr-Pro-Asp-Gly-AlaStarting pH, temperature, moisture and bulking agentMoisture, temperature and especially bulking agent type affected degradation; starting pH did not reach significance
Strickley and Anderson, 1996Human insulin freeze-dried from pH 2 to 5 solutionsWater content, at 35 °CDegradation rose with water content, even well below the glass transition
Prestrelski et al., 1993Several proteins and poly-L-lysine, a model polypeptideDrying with and without stabilizersDrying changed secondary structure; certain stabilizers preserved the native structure
Johnson et al., 2002Four proteins in developmentMannitol and sucrose mixturesCrystalline mannitol allowed primary drying at -10 °C; sucrose alone would have needed below -35 °C to avoid collapse

Oliyai and colleagues used a factorial design on a six-residue peptide containing aspartic acid. Residual moisture, temperature and the type of bulking agent all had significant effects. The type of bulking agent, amorphous or crystalline, stood out. Whether moisture and temperature mattered also depended on the excipient used.

Strickley and Anderson measured water in insulin powders by Karl Fischer titration and tracked breakdown by HPLC. Degradation produced deamidated insulin and covalent dimers. Its rate approached the solution rate at the water content needed to cause a glass transition. The reactive step "occurs readily even in the glassy state," the authors wrote.

Prestrelski and colleagues used infrared spectroscopy to compare proteins before and after drying. For several proteins the changes were partly irreversible, with denaturation and aggregation seen after rehydration. Similar transitions appeared in poly-L-lysine after lyophilization, and stabilizing additives inhibited them.

Johnson and colleagues describe sucrose as a lyoprotectant and mannitol as a bulking agent. Because the mannitol crystallized, primary drying could run much warmer without collapse.

Most of this literature concerns proteins rather than short peptides. The two peptide-specific studies above point the same way, but they cover only an aspartic acid model peptide and insulin.

What else is in a vial of lyophilized peptide?

Three other things can sit alongside the peptide: excipients, a counterion and residual water.

Excipients give the cake its structure and protect the molecule. Mannitol appears on all three labels in Table 3. The secretin label also lists L-cysteine hydrochloride and sodium chloride, and the bivalirudin label lists sodium hydroxide to adjust pH.

Counterions come from manufacturing. The bivalirudin label describes the active ingredient as bivalirudin trifluoroacetate. It states peptide content as the free peptide, with an average salt weight about one tenth higher. Its trifluoroacetic acid content ranges from 1.7 to 2.6 equivalents.

Counterions can change cell results. In the Cornish study, TFA at 10 to 100 nanomolar reduced cell numbers in fetal rat osteoblast cultures after 24 hours. TFA salts of amylin and calcitonin produced less proliferation than their hydrochloride salts. The authors said this could hide a real effect or create a false one. This was cell research only.

Residual water is the third component. FDA's guide calls "the amount of moisture present in vials" an obvious concern for lyophilized products. For research-grade material, water content and counterion can appear as lines on a certificate of analysis, explained in the guide to reading a COA.

What do FDA labels say about lyophilized peptide medicines?

Several FDA-approved peptide medicines are supplied as lyophilized solids. Their labels show that freeze-drying does not set one storage rule. Each product's conditions rest on its own stability data.

Table 3

What do FDA labels say about lyophilized peptide medicines

LabelPeptide as described on the labelForm and saltStorage stated on the label
Bivalirudin (Sandoz)Synthetic peptide of 20 amino acidsSterile white lyophilized cake; trifluoroacetate salt20 °C to 25 °C, with excursions to 15 °C to 30 °C permitted
Cetrotide (cetrorelix acetate)Synthetic decapeptide with GnRH antagonist activitySterile lyophilized powder; acetate saltRefrigerated, 2 °C to 8 °C; tray kept in the outer carton to protect from light
ChiRhoStim (human secretin)27 amino acids, identical to the natural hormoneLyophilized white cake powder; acetate salt-20 °C (freezer); protect from light

Bivalirudin is labeled for controlled room temperature, Cetrotide for a refrigerator and ChiRhoStim for a freezer. All three are dry solids, yet their labeled temperatures span about 45 degrees Celsius.

FDA's guide explains where such conditions come from. "The expiration date and moisture limit should be established based on worst case data," it says. Stability data should come from the batches with the higher moisture content. The peptide storage guide explains how re-test and expiry dates are defined.

No. Lyophilization is a manufacturing process; it says nothing about identity, purity or legal status. Research-grade lyophilized peptides are laboratory reagents with no FDA-approved label. Any storage statement or expiry date comes from the supplier.

A freeze-dried form does not guarantee quality. Ashraf and colleagues made test purchases from six illegal online pharmacies selling semaglutide. Three vials of lyophilized powder arrived. Measured purity was 7.7% to 14.37%, against 99% claimed, and endotoxin was found in all three. No viable microorganisms were found at the time of testing.

Purity is measured separately, usually by HPLC, as the HPLC purity guide describes. A research-use-only label does not make a product legal or safe for people. See research use only explained and the risks of human use of research peptides.

Frequently asked questions

What does lyophilized mean?

Freeze-dried. A solution is frozen, its ice is removed under vacuum by sublimation, and remaining water is removed by desorption.

Is a lyophilized peptide still a peptide?

Yes. Freeze-drying removes water and leaves the amino acid sequence unchanged when the process works as intended. Degradation during processing or storage can still create related impurities.

Why are peptides freeze-dried?

Mainly for shelf life. FDA's inspection guide says products are lyophilized because of their instability in solution.

Do lyophilized peptides still degrade?

Yes. Laboratory studies describe deamidation, peptide bond cleavage, oxidation and aggregation in the solid state, at rates that depend on moisture, temperature and excipients.

What is meltback?

FDA describes meltback as a form of cake collapse caused by incomplete sublimation in the vial. It can leave a pocket of moisture and may increase degradation.

Does freeze-drying sterilize a peptide?

No. In sterile manufacturing the solution is filter-sterilized before filling and handled aseptically. FDA notes that contents can be contaminated until vials are sealed.

Are research-grade lyophilized peptides FDA-approved?

No. A research-grade peptide is a laboratory reagent with no FDA-approved label. A research-use-only label does not make it legal or safe for people.

What to know now

  • Lyophilization is freeze-drying: freezing, primary drying by sublimation and secondary drying by desorption.
  • FDA's inspection guide says products are lyophilized because of their instability in solution.
  • Laboratory studies show dry peptides still degrade, with moisture, temperature and excipients setting the rate.
  • A vial usually holds excipients, a counterion and some water alongside the peptide.
  • Approved lyophilized peptide medicines carry storage conditions from a freezer to room temperature, set by stability data.

What we’re watching

  • More solid-state stability studies on short peptides; much of the published work concerns proteins.
  • Independent testing of lyophilized peptide products sold online; the study cited here analyzed three vials.
  • Label updates as new peptide medicines supplied in lyophilized form reach the market.

Also in the library

Sources: U.S. Food and Drug Administration 1993, Guide to inspections of lyophilization of parenterals; Flosdorf 1935, The Journal of Immunology, 29; Cornish 1999, American Journal of Physiology, 277; Tang 2004, Pharmaceutical Research, 21; Wang 2000, International Journal of Pharmaceutics, 203; Lai 1999, Journal of Pharmaceutical Sciences, 88; Oliyai 1994, Pharmaceutical Research, 11; Strickley 1996, Pharmaceutical Research, 13; Prestrelski 1993, Biophysical Journal, 65; Johnson 2002, Journal of Pharmaceutical Sciences, 91; Sandoz Inc 2019, Bivalirudin prescribing information; EMD Serono 2025, Cetrotide (cetrorelix acetate) prescribing information; ChiRhoClin 2025, ChiRhoStim (human secretin) prescribing information; Ashraf 2024, Journal of Medical Internet Research, 26. All 14 citations

Back to the research library

References

  1. U.S. Food and Drug Administration. (1993). Guide to inspections of lyophilization of parenterals. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/lyophilization-parenteral-793
  2. Flosdorf, E. W., & Mudd, S. (1935). Procedure and apparatus for preservation in "lyophile" form of serum and other biological substances. The Journal of Immunology, 29(5), 389-425. https://doi.org/10.4049/jimmunol.29.5.389
  3. Cornish, J., Callon, K. E., Lin, C. Q., Xiao, C. L., Mulvey, T. B., Cooper, G. J., & Reid, I. R. (1999). Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. American Journal of Physiology, 277(5), E779-E783. https://pubmed.ncbi.nlm.nih.gov/10567002/
  4. Tang, X., & Pikal, M. J. (2004). Design of freeze-drying processes for pharmaceuticals: practical advice. Pharmaceutical Research, 21(2), 191-200. https://pubmed.ncbi.nlm.nih.gov/15032301/
  5. Wang, W. (2000). Lyophilization and development of solid protein pharmaceuticals. International Journal of Pharmaceutics, 203(1-2), 1-60. https://pubmed.ncbi.nlm.nih.gov/10967427/
  6. Lai, M. C., & Topp, E. M. (1999). Solid-state chemical stability of proteins and peptides. Journal of Pharmaceutical Sciences, 88(5), 489-500. https://pubmed.ncbi.nlm.nih.gov/10229638/
  7. Oliyai, C., Patel, J. P., Carr, L., & Borchardt, R. T. (1994). Chemical pathways of peptide degradation. VII. Solid state chemical instability of an aspartyl residue in a model hexapeptide. Pharmaceutical Research, 11(6), 901-908. https://pubmed.ncbi.nlm.nih.gov/7937533/
  8. Strickley, R. G., & Anderson, B. D. (1996). Solid-state stability of human insulin. I. Mechanism and the effect of water on the kinetics of degradation in lyophiles from pH 2-5 solutions. Pharmaceutical Research, 13(8), 1142-1153. https://pubmed.ncbi.nlm.nih.gov/8865303/
  9. Prestrelski, S. J., Tedeschi, N., Arakawa, T., & Carpenter, J. F. (1993). Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophysical Journal, 65(2), 661-671. https://pubmed.ncbi.nlm.nih.gov/7693001/
  10. Johnson, R. E., Kirchhoff, C. F., & Gaud, H. T. (2002). Mannitol-sucrose mixtures: versatile formulations for protein lyophilization. Journal of Pharmaceutical Sciences, 91(4), 914-922. https://pubmed.ncbi.nlm.nih.gov/11948529/
  11. Sandoz Inc. (2019). Bivalirudin prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb
  12. EMD Serono. (2025). Cetrotide (cetrorelix acetate) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aca7768e-28a7-4027-b1d8-e66247665f79
  13. ChiRhoClin. (2025). ChiRhoStim (human secretin) prescribing information. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4dfe70f-0a86-4488-9ba1-dcd8f86cbfcd
  14. Ashraf, A. R., Mackey, T. K., Vida, R. G., Kulcsár, G., Schmidt, J., Balázs, O., Domián, B. M., Li, J., Csákó, I., & Fittler, A. (2024). Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: Market surveillance, content analysis, and product purchase evaluation study. Journal of Medical Internet Research, 26, e65440. https://pubmed.ncbi.nlm.nih.gov/39509151/